意美止吐效果维持多久？意美最多只能吃几次

Yimei is the first neurokinin-1 (NK-1) receptor blocker approved by the US FDA in 2003. Blocks the effects of substance P by binding to NK-1 receptors (mainly found in the central nervous system and its periphery). It is currently approved in more than 75 countries. Today let’s find out how long the antiemetic effect of Yimei lasts? How many times can I eat it at most?

Yimei Usage and Dosage:

Imeda is a three-day intervention and includes a course of treatment with a corticosteroid and a 5-HT3 antagonist. The recommended dose of Yimei is 125 mg taken orally one hour before chemotherapy on the first day, and 80 mg once daily in the morning on the second and third days.

Yimei can be taken with or without food. Applicable and contraindication groups for taking the medicine:

1. Suitable for patients who experience vomiting symptoms during chemotherapy;

2. Contraindications: People who are allergic to any component of Yimei Capsules; patients who are taking pimozide, terfenadine, astemizole and other drugs.

3. Pregnant women, the elderly, and children are not allowed to take this medicine. Pregnant women and lactating women are not allowed to take this medicine. The safety of this medicine is unknown for children, so it should be used with caution. There are no clear contraindications for the elderly.

Yimei’s antiemetic mechanism is:

Yimei can bind to neurokinin-1 receptors, block substance P, and improve symptoms of nausea and vomiting. Yimei also has a high binding rate to protein. Combining this drug with other antiemetics can improve the antiemetic effect and improve patients' treatment compliance.

Aprepitant has a brand-new pharmacological mechanism of action, is selective and has high affinity for NK1 receptors, and can maintain long-term central activity. It has significantly improved the CR rate of acute and delayed CINV, and has especially made new breakthroughs in the control of delayed CINV.

The results of multiple studies have confirmed that the antiemetic regimen of combining aprepitant with the 5-HT3 receptor antagonist + dexamethasone regimen is more effective in preventing acute or delayed vomiting caused by chemotherapy regimens with moderate and high emetogenic risks, without significantly increasing toxic effects.

Aprepitant has a unique mode of action as it is a selective and high-affinity antagonist of the human substance P Neurokinin1 (NK1) receptor.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.